EuropeResearch and clinical trials
89 pregnancies reviewed in women with long-chain fatty acid disorders; most had good outcomes
Pregnancy information on 39 women with a disease in this group was collected from doctors in Europe and North America.
Inborn errors of metabolism
An inherited disease in which the body cannot turn very long-chain fats into energy. The heart, liver and muscles can be affected. Fasting, illness and heavy exercise trigger problems.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
Orphanet has a guideline for emergency doctors for this disease (language: French, English). See on Orphanet
This page is translated from the Turkish original.
This disease is followed through the “Inborn errors of metabolism” group.
The VLCAD enzyme breaks down very long-chain fatty acids. When this enzyme is missing, these fats cannot be turned into energy. Fat waste products that build up can damage the heart, liver and muscles. There are three types, which begin in infancy, in childhood or later.
Symptoms vary depending on the type of the disease. Fasting, illness, exercise, heat or cold can trigger episodes.
The blood is checked for fat waste products called acylcarnitines, and a typical pattern is seen. The diagnosis is confirmed with a genetic test. If needed, a special enzyme test is done on skin or blood cells.
The basis of treatment is diet. A meal plan low in long-chain fat and containing special fats is followed. Fasting is avoided, and babies are fed often. Avoiding heavy exercise helps prevent muscle breakdown. In the USA, there is an approved special fat treatment for this group of diseases. The heart and blood values are checked regularly. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually carriers who show no symptoms. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Recessive diseases can be more common when relatives marry each other. Testing brothers and sisters as well is recommended. Genetic counselling is recommended.
Source: MedlinePlus Genetics: Very long-chain acyl-CoA dehydrogenase deficiency · GeneReviews: Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
EuropeResearch and clinical trials
Pregnancy information on 39 women with a disease in this group was collected from doctors in Europe and North America.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
EUNew treatments and approvals
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy.
USANew treatments and approvals
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia.
EuropeResearch and clinical trials
A total of 58 patients from 34 centers in seven European countries were followed.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:26793
No separate ICD-11 code; WHO classifies this disease under: 5C52.01
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.